Cargando…

Non-altered incretin secretion in women with impaired fasting plasma glucose in the early stage of pregnancy: a case control study

BACKGROUNDS: Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) may be involved in pathogenesis of gestational diabetes mellitus (GDM). The aim was to compare GLP-1 and GIP production in fasting state and during 3 h mixed meal tolerance test (MMTT) measured by mean ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Krystynik, Ondrej, Karasek, David, Kahle, Michal, Kubickova, Veronika, Macakova, Dominika, Cibickova, Lubica, Mraz, Milos, Haluzik, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885569/
https://www.ncbi.nlm.nih.gov/pubmed/36717953
http://dx.doi.org/10.1186/s13098-023-00981-7
_version_ 1784879955286425600
author Krystynik, Ondrej
Karasek, David
Kahle, Michal
Kubickova, Veronika
Macakova, Dominika
Cibickova, Lubica
Mraz, Milos
Haluzik, Martin
author_facet Krystynik, Ondrej
Karasek, David
Kahle, Michal
Kubickova, Veronika
Macakova, Dominika
Cibickova, Lubica
Mraz, Milos
Haluzik, Martin
author_sort Krystynik, Ondrej
collection PubMed
description BACKGROUNDS: Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) may be involved in pathogenesis of gestational diabetes mellitus (GDM). The aim was to compare GLP-1 and GIP production in fasting state and during 3 h mixed meal tolerance test (MMTT) measured by mean area under the curve (AUC) between pregnant women with normal and impaired fasting glucose in an early phase of pregnancy, and healthy non-pregnant controls. METHODS: This study was undertaken as a case–control study. Repeated measurement of fasting plasma glucose ≥ 5.1 mmol/L and < 7.0 mmol/L during the first trimester of pregnancy and exclusion of overt diabetes according to IADSPG criteria was used to find women with impaired fasting glucose (n = 22). Age-matched controls consisted of healthy pregnant (n = 25) and non-pregnant (n = 24) women. In addition to incretins, anthropometric parameters and markers of insulin resistance and beta-cell function were assessed. Variables were summarized as median (interquartile range). RESULTS: Fasting GLP-1 and GIP concentration or their AUC during MMTT did not significantly differ between pregnant women with impaired fasting plasma glucose [GLP-1(AUC) 19.0 (53.1) and GIP(AUC) 302 (100) pg/mL/min] and healthy pregnant women [GLP-1(AUC) 16.7 (22.3) and GIP(AUC) 297 (142) pg/mL/min] or non-pregnant controls [GLP-1(AUC) 16.8 (9.8) and for GIP(AUC) 313 (98) pg/mL/min]. Although women with impaired fasting glucose were more obese and showed decreased beta-cell function, there were not significant correlations between incretin production and parameters of insulin secretion, insulin resistance, or obesity. CONCLUSIONS: Women with impaired fasting plasma glucose did not show altered incretin production in the first trimester of pregnancy. In contrast to type 2 diabetes, impaired incretin secretion does not seem to play a major role in the early development of GDM.
format Online
Article
Text
id pubmed-9885569
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98855692023-01-31 Non-altered incretin secretion in women with impaired fasting plasma glucose in the early stage of pregnancy: a case control study Krystynik, Ondrej Karasek, David Kahle, Michal Kubickova, Veronika Macakova, Dominika Cibickova, Lubica Mraz, Milos Haluzik, Martin Diabetol Metab Syndr Research BACKGROUNDS: Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) may be involved in pathogenesis of gestational diabetes mellitus (GDM). The aim was to compare GLP-1 and GIP production in fasting state and during 3 h mixed meal tolerance test (MMTT) measured by mean area under the curve (AUC) between pregnant women with normal and impaired fasting glucose in an early phase of pregnancy, and healthy non-pregnant controls. METHODS: This study was undertaken as a case–control study. Repeated measurement of fasting plasma glucose ≥ 5.1 mmol/L and < 7.0 mmol/L during the first trimester of pregnancy and exclusion of overt diabetes according to IADSPG criteria was used to find women with impaired fasting glucose (n = 22). Age-matched controls consisted of healthy pregnant (n = 25) and non-pregnant (n = 24) women. In addition to incretins, anthropometric parameters and markers of insulin resistance and beta-cell function were assessed. Variables were summarized as median (interquartile range). RESULTS: Fasting GLP-1 and GIP concentration or their AUC during MMTT did not significantly differ between pregnant women with impaired fasting plasma glucose [GLP-1(AUC) 19.0 (53.1) and GIP(AUC) 302 (100) pg/mL/min] and healthy pregnant women [GLP-1(AUC) 16.7 (22.3) and GIP(AUC) 297 (142) pg/mL/min] or non-pregnant controls [GLP-1(AUC) 16.8 (9.8) and for GIP(AUC) 313 (98) pg/mL/min]. Although women with impaired fasting glucose were more obese and showed decreased beta-cell function, there were not significant correlations between incretin production and parameters of insulin secretion, insulin resistance, or obesity. CONCLUSIONS: Women with impaired fasting plasma glucose did not show altered incretin production in the first trimester of pregnancy. In contrast to type 2 diabetes, impaired incretin secretion does not seem to play a major role in the early development of GDM. BioMed Central 2023-01-30 /pmc/articles/PMC9885569/ /pubmed/36717953 http://dx.doi.org/10.1186/s13098-023-00981-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Krystynik, Ondrej
Karasek, David
Kahle, Michal
Kubickova, Veronika
Macakova, Dominika
Cibickova, Lubica
Mraz, Milos
Haluzik, Martin
Non-altered incretin secretion in women with impaired fasting plasma glucose in the early stage of pregnancy: a case control study
title Non-altered incretin secretion in women with impaired fasting plasma glucose in the early stage of pregnancy: a case control study
title_full Non-altered incretin secretion in women with impaired fasting plasma glucose in the early stage of pregnancy: a case control study
title_fullStr Non-altered incretin secretion in women with impaired fasting plasma glucose in the early stage of pregnancy: a case control study
title_full_unstemmed Non-altered incretin secretion in women with impaired fasting plasma glucose in the early stage of pregnancy: a case control study
title_short Non-altered incretin secretion in women with impaired fasting plasma glucose in the early stage of pregnancy: a case control study
title_sort non-altered incretin secretion in women with impaired fasting plasma glucose in the early stage of pregnancy: a case control study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885569/
https://www.ncbi.nlm.nih.gov/pubmed/36717953
http://dx.doi.org/10.1186/s13098-023-00981-7
work_keys_str_mv AT krystynikondrej nonalteredincretinsecretioninwomenwithimpairedfastingplasmaglucoseintheearlystageofpregnancyacasecontrolstudy
AT karasekdavid nonalteredincretinsecretioninwomenwithimpairedfastingplasmaglucoseintheearlystageofpregnancyacasecontrolstudy
AT kahlemichal nonalteredincretinsecretioninwomenwithimpairedfastingplasmaglucoseintheearlystageofpregnancyacasecontrolstudy
AT kubickovaveronika nonalteredincretinsecretioninwomenwithimpairedfastingplasmaglucoseintheearlystageofpregnancyacasecontrolstudy
AT macakovadominika nonalteredincretinsecretioninwomenwithimpairedfastingplasmaglucoseintheearlystageofpregnancyacasecontrolstudy
AT cibickovalubica nonalteredincretinsecretioninwomenwithimpairedfastingplasmaglucoseintheearlystageofpregnancyacasecontrolstudy
AT mrazmilos nonalteredincretinsecretioninwomenwithimpairedfastingplasmaglucoseintheearlystageofpregnancyacasecontrolstudy
AT haluzikmartin nonalteredincretinsecretioninwomenwithimpairedfastingplasmaglucoseintheearlystageofpregnancyacasecontrolstudy